FAQ

Bangladesh prices come from the MedEx drug registry: DGDA-registered list unit prices collected brand by brand with manufacturer, strength and pack — 387 records, collected September 2026. Clinical content comes from FDA/EMA labels and national drug registries.

Three reasons: brand premium (originator or leading local maker versus a smaller producer), pack configuration (retail strips versus full cases) and channel (pharmacy retail versus hospital tender). That is why the tables show a range rather than one number.

We convert on a public FX basis (1 USD = 122.87 BDT, September 2026) purely for comparison. The binding price is the supplier quotation at the exchange rate of the order day.

Price tables are re-verified quarterly and the FX basis is refreshed with the data date on every page. Molecules with volatile pricing (recently launched targeted therapies) are checked more often.

Four checks: national GMP certification (DGDA in Bangladesh, CDSCO in India, Lao FDA, etc.); product registration with a registration number; a batch number plus certificate of analysis covering assay, dissolution and impurities; and a track record of exports with a functioning batch-traceability system.

Small-molecule generics are chemically identical and need only bioequivalence data. Monoclonal antibodies, insulins and other peptides are biologics: their "similar" versions require comparability work (physicochemical characterisation, functional assays, immunogenicity), so a biosimilar is not the identical molecule and interchangeability is a clinical decision.

Yes. Bangladesh is a WTO least-developed-country member with a pharmaceutical patent exemption running to 2033, so manufacturers there can legally produce and sell molecules still under patent elsewhere. Importing those products into your own country must follow local law — registration or a named-patient authorisation.

A valid prescription from the treating physician, the diagnostic and mutation-test report (essential for targeted therapy), patient or institution details (importer/pharmacy licence), and the destination country’s import permit or named-patient approval.

Common destinations: Bangladesh, India, Pakistan, Philippines, Malaysia, Singapore, Thailand, Vietnam, Indonesia, Nigeria, Kenya. Whether a specific shipment can move depends on destination law, which we confirm before quoting.

Monoclonal antibodies, insulins and GLP-1 products need 2–8°C end-to-end, using temperature-logged cold boxes or dry ice, with the requirement stated on the air waybill. Check the temperature log and packaging integrity on arrival.

Standard is a corporate wire transfer (T/T), with partial prepayment on a first order; large orders can ship in instalments. We do not accept personal crypto payments and we do not ship before payment.

From Bangladesh to Southeast Asia typically 3–10 days to dispatch plus 5–20 days clearance; each molecule and country page states its own lead time. Indian and Lao sources differ.

Warning signs: a price far below the lowest registered list price, no batch number or COA, poor print quality, odd batch/expiry formats, and a seller unwilling to show manufacturer provenance. On arrival check the batch number and anti-counterfeit label, and keep packaging and documents for traceability.

No. Targeted oncology drugs, immunosuppressants and insulins all require physician assessment and monitoring (liver function, blood counts, QT interval, glucose). Self-medication can be ineffective and dangerous.

No. This site is a knowledge and price-intelligence resource. We do not sell prescription medicines to individual patients and we do not give medical advice. We supply sourcing intelligence and channels to licensed institutions.